Detalhe da pesquisa
1.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Blood
; 138(21): 2042-2050, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407543
2.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood
; 138(21): 2031-2041, 2021 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407542
3.
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
Am J Hematol
; 94(11): 1236-1243, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31456269
4.
First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
Am J Hematol
; 92(11): 1214-1223, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28815757
5.
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Leukemia
; 38(5): 1072-1080, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38548962
6.
Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation.
Pathophysiology
; 30(3): 296-313, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37606386
7.
Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience.
Front Oncol
; 13: 1138683, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37007128
8.
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Leukemia
; 37(3): 617-626, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36717654
9.
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Leuk Lymphoma
; 62(4): 918-926, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33210570